Figure S5 from A Randomized Phase II Study: CRS207/GVAX plus Anti–PD‐1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC

2026 Open access

Read full text
Authors: Katherine M. Bever, Amanda L. Huff, Ludmila Danilova, Meredith Wetzel, Joseph A. Tandurella, Jennifer N. Durham, Tingchang Wang, Jae Sung Lee, Erin M. Coyne, Janelle Marie Montagne, Jacob T. Mitchell, Alexei Hernandez
+7 more Sarah M. Shin, Robert A. Anders, Hao Wang, Elana Judith Fertig, Elizabeth M. Jaffee, Dung Thi Le, Won Jin Ho
DOI: 10.1158/2326-6066.31484392
Cited by: 0

Abstract

Detection of pre-existing MSLN- or KRAS-specific T cells in the periphery of treated patients

Fields of Study & Subjects

Immunotherapy and Immune Responses Pancreatic and Hepatic Oncology Research Cancer Immunotherapy and Biomarkers

Publication details

Publication date
4 March 2026
Language
EN